McMaster Health Science
Welcome,         Profile    Billing    Logout  
 5 Trials 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Chan, Anthony TC
FiXET, NCT02486666: Pilot Feasibility and Safety of Administering Weight Adjusted Fixed LMWH Dose

Recruiting
3
20
Canada, US
Enoxaparin, Enoxaparin sodium
Hamilton Health Sciences Corporation, IWK Health Centre, Children's Hospital of Philadelphia, Children's Hospital of Eastern Ontario
Venous Thromboembolism
12/22
12/22
NRG-HN001, NCT02135042: Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

Active, not recruiting
2/3
685
Canada, US, RoW
Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Clinical Observation, Fluorouracil, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-FU, AccuSite, Actino-Hermal, Adrucil, Arumel, Cytosafe, Efudex, Efurix, Fiverocil, Fluoro Uracil, Fluoroplex, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Flurox, Ribofluor, Ro 2-9757, Ro-2-9757, Timazin, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemzar, LY-188011, Intensity-Modulated Radiation Therapy, IMRT, Intensity Modulated RT, Intensity-Modulated Radiotherapy, Laboratory Biomarker Analysis, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Quality-of-Life Assessment, Quality of Life Assessment
NRG Oncology, National Cancer Institute (NCI)
Epstein-Barr Virus Infection, Stage II Nasopharyngeal Carcinoma, Stage III Nasopharyngeal Carcinoma, Stage IVA Nasopharyngeal Carcinoma, Stage IVB Nasopharyngeal Carcinoma
02/26
02/31
PRESent-2, NCT05789524: The Efficacy and Safety of SerpinPC in Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B

Recruiting
2
120
Europe, Canada, US, RoW
SerpinPC, Activated Protein C (APC) inhibitor
ApcinteX Ltd, Centessa Pharmaceuticals plc
Hemophilia A, Hemophilia B
03/26
06/26
AXEL, NCT04562441: NPC - Study : Axitinib-Avelumab

Active, not recruiting
2
43
RoW
Axitinib, Avelumab
Chinese University of Hong Kong
Recurrent or Metastatic NPC
12/26
12/27
PHOSPHATE, NCT03573089: Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease

Recruiting
N/A
3600
Europe, Canada, RoW
Liberal phosphate target, Intensive phosphate target
The University of Queensland, National Health and Medical Research Council, Australia, Applied Health Research Centre, Cambridge University Hospitals NHS Foundation Trust, University of Otago
Kidney Failure, Chronic, Hyperphosphatemia
12/27
12/28
PRESent-5, NCT05605678: Hemophilia Non-Interventional Study Prior to SerpinPC Intervention

Recruiting
N/A
200
Europe, Canada, US, RoW
No Intervention
ApcinteX Ltd, Centessa Pharmaceuticals plc
Hemophilia A, Hemophilia B
11/24
11/24
Protect-NOW, NCT03695978: Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia a Patients

Recruiting
N/A
200
Europe, Canada, US, RoW
Octapharma
Haemophilia a
06/30
06/30

Download Options